Seminars in arthritis and rheumatism最新文献

{"title":"Corrigendum to “The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time” [Seminars in Arthritis and Rheumatism 55 (2022):152010]","authors":"John H. Stone , P. Jane McDowell , David R.W. Jayne , Peter A. Merkel , Joanna Robson , Naomi J. Patel , Yuqing Zhang , Huibin Yue , Pirow Bekker , Liam G. Heaney","doi":"10.1016/j.semarthrit.2024.152496","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152496","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001367/pdfft?md5=ca4533a61e8eedfb7ac6376804e74df0&pid=1-s2.0-S0049017224001367-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141485624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TNFRSF11A variants contribute to systemic autoinflammatory diseases: A case series of 12 patients","authors":"Vasileios Papatheodorou ,&nbsp;Charalampos Gerodimos ,&nbsp;Antonios Dimitrakopoulos ,&nbsp;Efrosini Lada ,&nbsp;Maria G Tektonidou ,&nbsp;Anastasios Germenis ,&nbsp;Petros P Sfikakis ,&nbsp;Katerina Laskari","doi":"10.1016/j.semarthrit.2024.152505","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152505","url":null,"abstract":"<div><h3>Background</h3><p>Limited evidence suggests that variants in <em>TNFRSF11A</em> gene, encoding RANK, may contribute to systemic autoinflammatory disease (SAID).</p></div><div><h3>Aim/Methods</h3><p>To estimate the prevalence of <em>TNFRSF11A</em> variants in a cohort of patients with SAIDs screened for 26 related genes and describe the disease phenotypic expression.</p></div><div><h3>Results</h3><p>A total of 12 out of 167 patients, 7 males, aged (median) 38 years at disease onset, yielded at least one <em>TNFRSF11A</em> rare variant. All patients carried a coexisting variant in at least one other SAID-related gene, most frequently <em>MEFV</em> (6 patients), but also <em>TNFRSF1A, NOD2, NLRP3, NLRP7, MVK, IL36RN, RBCK1, PLCG2</em> and <em>PSMB8</em>. SAID episodes lasting (median) 9 days manifested with high grade fever (91%), myalgias (75%), malaise (67%), serositis (58%), arthralgias/arthritis (58%), gastrointestinal involvement (33%), and rash (25%), and responded to corticosteroids. The most common initial clinical diagnosis was TNF-associated periodic fever syndrome (TRAPS), which was, however, confirmed, in only one patient. The emergence of <em>MEFV</em> variations supported the diagnosis of atypical Familial Mediterranean Fever in two cases, whereas the diagnosis of Yao syndrome was speculated in two patients with <em>NOD2</em> variants. The presence of atypical disease and the inability of defining diagnosis in the remaining 7 patients, supported the possible involvement of <em>TNFRSF11A</em> variants in the phenotypic expression of SAIDs.</p></div><div><h3>Conclusion</h3><p><em>TNFRSF11A</em> variants, occurring in 7% of SAID patients always in combination with other SAID-related gene variants, contribute to the development of an autoinflammatory syndrome resembling to TRAPS. Additional studies to confirm novel pathogenic SAID pathways are clearly warranted.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141606427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum uric acid, a potential biomarker for interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis","authors":"Huaiya Xie, Junping Fan","doi":"10.1016/j.semarthrit.2024.152510","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152510","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141838709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to commentary on IgG4-related uveitis. A French cohort and literature review","authors":"Emily Stuchfield-Denby, B. D. S. Marie, N. Schleinitz","doi":"10.1016/j.semarthrit.2024.152514","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152514","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing composite outcome measures: Insights on weighting components from OMERACT 2023","authors":"George A Wells ,&nbsp;Francis Guillemin ,&nbsp;Peter A. Merkel ,&nbsp;Maarten de Wit ,&nbsp;Sarah Mackie ,&nbsp;Lyn March ,&nbsp;Gunnar Tómasson ,&nbsp;Lauren K. King ,&nbsp;Sam Michel Cembalo ,&nbsp;Shawna Grosskleg ,&nbsp;Lara J. Maxwell ,&nbsp;Sara Monti ,&nbsp;Kaitlin A. Quinn ,&nbsp;Beverley J Shea ,&nbsp;Peter Tugwell ,&nbsp;Dorcas Beaton","doi":"10.1016/j.semarthrit.2024.152503","DOIUrl":"10.1016/j.semarthrit.2024.152503","url":null,"abstract":"<div><h3>Objective</h3><p>The OMERACT Composite Working Group hosted a workshop at OMERACT 2023 to explore the complexities of weighting components in the development of composite outcomes. This study presents the methodology and findings of this workshop, exploring the complexities of weighting the individual components of composite outcome measures.</p></div><div><h3>Methods</h3><p>The workshop featured a multifaceted program, beginning with a plenary session that introduced the concept of composite outcomes, shared a patient's journey with rheumatic disease through a narrative, illustrated a composite outcome for Osteoarthritis Flares, and outlined the five domains selected for this composite outcome. A breakout exercise engaged participants in ranking and assigning weights to these domains, followed by group discussions to reach a consensus on weights. The workshop concluded with another plenary session that discussed various weighting approaches, including discrete choice and conjoint analysis from the ANCA-Associated Vasculitis working group, and outlined future directions for research on composite outcome methods.</p></div><div><h3>Results</h3><p>The breakout exercise revealed the challenges in assigning relative importance to different domains, highlighting the variability in participant perspectives. Consensus discussions highlighted the diversity in approaches to weighting, the need for appropriate methods to determine domain weights and the impact of such weights on the interpretation of composite scores.</p></div><div><h3>Conclusion</h3><p>The OMERACT 2023 workshop underscored the significance of a systematic approach to weighting components in composite outcome development. It highlighted the complexity of achieving consensus on the importance of domains and the role of incorporating the perspectives of patient research partners in this process. Future research directions include refining weighting methodologies, moving composites through the OMERACT Filter and enhancing understanding of their implications for clinical trials. The findings contribute to the ongoing discourse on optimizing composite outcome measures in rheumatology and beyond, advocating for a balanced integration of scientific rigour and patient-centeredness in their development.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142136783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary central nervous system vasculitis with intracranial aneurysm","authors":"Carlo Salvarani ,&nbsp;Robert D. Brown Jr ,&nbsp;Teresa J.H. Christianson ,&nbsp;John Huston III ,&nbsp;Caterina Giannini ,&nbsp;Gene G. Hunder","doi":"10.1016/j.semarthrit.2024.152506","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152506","url":null,"abstract":"<div><h3>Background</h3><p>Unruptured intracranial aneurysms (UIAs) are rarely reported in primary central nervous system vasculitis (PCNSV). In this study we described the clinical findings, response to therapy, and outcomes of UIA in a large cohort of PCNSV patients.</p></div><div><h3>Methods</h3><p>We retrospectively studied 216 consecutive patients with PCNSV, selected by predetermined diagnostic criteria, who were seen during a 40-year period. UIAs were identified on cerebral angiography. The clinical, laboratory, radiologic and pathologic findings, management, and outcomes of patients with UIA were described and compared with those without UIA.</p></div><div><h3>Results</h3><p>12/216 (5.5 %) PCNSV patients had at least one UIA. Two patients underwent biopsies; one yielded negative results, while the other showed necrotizing vasculitis. Eleven patients had evidence of UIA on angiogram at diagnosis. One patient developed an aneurysm during the follow-up associated with a worsening of vasculitic radiological findings. The most common presenting symptom for PCNSV in the setting of UIA was headache (67 %), followed by persistent neurologic deficit or stroke (50 %). Most patients with UIA presented with multiple cerebral infarcts on MRI (67 %), one patient had subarachnoid hemorrhage, and one left parieto-occipital intracerebral hematoma, both unrelated to the aneurysm. Black blood imaging was performed in 4 patients and 2 showed segmental circumferential mural enhancement involving multiple vessels. Two patients had 2 UIAs, while the other 10 had 1. The most frequent UIA location was internal carotid artery (50 %), followed by anterior cerebral artery (21 %). Ten of the UIAs were &lt; 5 mm in diameter, and 3 were 5–7 mm in diameter; the size was not available for one. All UIAs were unchanged in size and configuration during follow-up (median: 18.5 months; range 1–151 months) and no new aneurysms were detected. Compared to the 204 patients with PCNSV without a UIA, no significant clinical differences were observed, except for a reduced disability at last follow-up (<em>p</em> = 0.038).</p></div><div><h3>Conclusions</h3><p>UIAs uncommonly occur in PCNSV.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials","authors":"Liuting Zeng ,&nbsp;Kailin Yang ,&nbsp;Ganpeng Yu ,&nbsp;Junpeng Chen ,&nbsp;Zhiyong Long ,&nbsp;Wang Xiang ,&nbsp;Shuman Liu ,&nbsp;Yaru Zheng ,&nbsp;Yexing Yan ,&nbsp;Moujia Hao ,&nbsp;Lingyun Sun","doi":"10.1016/j.semarthrit.2024.152498","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152498","url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to assess the effectiveness and safety of mesenchymal stem cell (MSC) transplantation in the treatment of inflammatory arthritis.</p></div><div><h3>Methods</h3><p>Two researchers conducted a comprehensive search of Chinese and English databases from their inception until July 2023. The literature screening and data extraction were then performed. Statistical analysis was carried out using RevMan 5.4 software.</p></div><div><h3>Results</h3><p>A total of 36 relevant RCTs, involving 2,076 participants, were ultimately included in this study. These RCTs encompassed four types of inflammatory arthritis, namely rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and systemic sclerosis (SSc). The results demonstrated that MSC therapy exhibited improvements in the Visual Analog Scale (VAS) for pain in OA patients (bone marrow: SMD=-0.95, 95 % CI: -1.55 to -0.36, <em>P</em> = 0.002; umbilical cord: SMD=-2.03, 95 % CI: -2.99 to -1.07, <em>P</em> &lt; 0.0001; adipose tissue: SMD=-1.26, 95 % CI: -1.99 to -0.52, <em>P</em> = 0.0009). Specifically, MSCs sourced from adipose tissue showed enhancements in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain (<em>P</em> = 0.0001), WOMAC physical function (<em>P</em> = 0.001), and total WOMAC scores (<em>P</em> = 0.0003). As for MSC therapy in RA, AS, and SSc, the current systematic review suggests a potential therapeutic effect of MSCs on these inflammatory arthritic conditions. Safety assessments indicated that MSC therapy did not increase the incidence of adverse events.</p></div><div><h3>Conclusion</h3><p>MSCs have the potential to alleviate joint pain and improve joint function in patients with inflammatory arthritis. Moreover, MSC therapy appears to be relatively safe and could be considered as a viable alternative treatment option for inflammatory arthritis.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients","authors":"Dimitrios A Pappas ,&nbsp;George Reed ,&nbsp;Kevin Kane ,&nbsp;Jeffrey R Curtis ,&nbsp;Christina Charles-Schoeman ,&nbsp;Jon T Giles ,&nbsp;Joel M Kremer","doi":"10.1016/j.semarthrit.2024.152504","DOIUrl":"10.1016/j.semarthrit.2024.152504","url":null,"abstract":"<div><h3>Background</h3><p>Cardiovascular disease (CVD) is the main cause of mortality in Rheumatoid Arthritis (RA).</p></div><div><h3>Objective</h3><p>To investigate the effect of biologic disease modifying anti-rheumatic drugs (bDMARDs) on lipids and CVD risk and evaluate associations with changes in systemic inflammation.</p></div><div><h3>Methods</h3><p>Patients with RA initiating a bDMARD were evaluated at baseline, 3 and 6 months later. Longitudinal mixed effects models examined the association of individual biologics with changes in lipid levelsm Reynolds Risk Score (RRS) and Framingham risk score. Mediation by CRP, clinical disease activity index (CDAI) or swollen joint count on lipid changes were modeled using structural equation models. The correlation between CRP changes and LDL changes was estimated. Changes of LDL-C at 6 months among patients with low baseline LDL-C (&lt;90 mg/dl) vs higher baseline LDL-C(90–130, and &gt;130 mg/dl) were compared. The association between LDL-C changes across baseline LDL-C groups and disease activity improvement was evaluated.</p></div><div><h3>Results</h3><p>1698 bDMARD initiations were analyzed. Patients initiating tocilizumab had a significant increase in lipid levels but RRS at 3 and 6 months was similar across all biologics. Framingham risk score increased for patients treated with tocilizumab. Mediator analyses were statistically significant for the effects of CRP on lipid levels. Increases in LDL-C from baseline were independent of clinical response. An association of changes from baseline CRP and LDL-C were observed across all of the bDMARDs studied.</p></div><div><h3>Conclusion</h3><p>Moderate increases in lipid levels on bDMARD treatment were not associated with an increased CVD risk by RRS regardless of the bDMARD initiated. Changes in CRP were significantly associated with changes in lipids in a mediator analysis.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study","authors":"Lien Moreel ,&nbsp;Albrecht Betrains ,&nbsp;Lennert Boeckxstaens ,&nbsp;Geert Molenberghs ,&nbsp;Koen Van Laere ,&nbsp;Ellen De Langhe ,&nbsp;Steven Vanderschueren ,&nbsp;Daniel Blockmans","doi":"10.1016/j.semarthrit.2024.152499","DOIUrl":"10.1016/j.semarthrit.2024.152499","url":null,"abstract":"<div><h3>Objectives</h3><p>To evaluate differences in presentation and outcome of giant cell arteritis (GCA) patients with and without polymyalgia rheumatica (PMR) symptoms.</p></div><div><h3>Methods</h3><p>Consecutive patients diagnosed with GCA between 2000 and 2020 and followed for ≥12 months at the University Hospitals Leuven (Belgium), were included retrospectively.</p></div><div><h3>Results</h3><p>We included 398 GCA patients, of which 181 (45%) with PMR symptoms. Patients with PMR symptoms had a longer symptom duration (11 vs 6 weeks, <em>p</em> &lt; 0.001). They less frequently reported fever (19% vs 28%, <em>p</em> = 0.030) and fatigue (52% vs 64%, <em>p</em> = 0.015) and tended to have less permanent vision loss (12% vs 19%, <em>p</em> = 0.052). There was no difference in the cumulative oral GC dose at 2 years (4.4 vs 4.3 g methylprednisolone, <em>p</em> = 0.571). However, those with PMR symptoms were treated with higher GC doses during subsequent follow-up (<em>p</em> &lt; 0.05 from 38 months after diagnosis) and had a lower probability of stopping GC (62% vs 71%, HR 0.74 [95%CI 0.58–0.94], <em>p</em> = 0.018) with a longer median duration of GC treatment (29 vs 23 months, <em>p</em> = 0.021). In addition, presence of PMR symptoms was associated with an increased risk of relapse (64% vs 51%, HR 1.38 [95%CI 1.06–1.79], <em>p</em> = 0.017) with a higher number of relapses (1.47 [95%CI 1.30–1.65] vs 1.16 relapses [95%CI 1.02–1.31], <em>p</em> = 0.007). Patients with PMR symptoms less frequently developed thoracic aortic aneurysms during follow-up (3% vs 11%, <em>p</em> = 0.005).</p></div><div><h3>Conclusion</h3><p>GCA patients with PMR symptoms had more recalcitrant disease with a higher risk of relapse and longer duration of GC treatment with need for higher GC doses.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound evaluation contrasts clinical disease activity evaluation in rheumatoid arthritis patients with concomitant anxiety or depression","authors":"Brigitte Michelsen ,&nbsp;Joseph Sexton ,&nbsp;Tore K Kvien ,&nbsp;Sella Aarestad Provan ,&nbsp;Hilde Berner Hammer","doi":"10.1016/j.semarthrit.2024.152502","DOIUrl":"10.1016/j.semarthrit.2024.152502","url":null,"abstract":"<div><h3>Objectives</h3><p>To compare disease activity as assessed by ultrasonography (US) between rheumatoid arthritis (RA) patients with and without anxiety or depression, and to compare clinical disease activity and sociodemographic measures between these patient groups.</p></div><div><h3>Methods</h3><p>Anxious or depressed patients were identified by EuroQoL-5D-3L question “I am not/moderately/extremely anxious or depressed.” US assessments of 36 joints and 4 tendons were performed and power Doppler (PD) and grey scale (GS) sum scores calculated (both range 0–120). Comparisons between anxious/depressed and not anxious/depressed patients were performed in unadjusted analyses, adjusted logistic regression, and sensitivity analyses.</p></div><div><h3>Results</h3><p>A total of 201 RA patients starting biological disease-modifying antirheumatic drugs were included (82 % women, mean age 52 years, disease duration 10 years). Hundred-and-nine patients (54.2 %) were moderately or extremely anxious/depressed. Median (IQR) PD (13 (4, 21) vs. 10 (3, 20), <em>p</em> = 0.53) and GS (28 (18, 42) vs. 25 (14, 41), <em>p</em> = 0.51) sum scores were similar between anxious/depressed and not anxious/depressed patients, respectively, whereas composite scores of disease activity were significantly worse in the anxious/depressed patients (<em>p</em> &lt; 0.001), as were also patient-reported outcomes, ESR, CRP and plasma calprotectin (all <em>p</em> ≤ 0.02). Sensitivity analyses confirmed these findings, except for CRP. Self-reported economy and sleep difficulties were also worse in the anxious/depressed patients and a higher proportion were not working (all <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>This study highlights the negative impact of anxiety and depression on RA patients in standard care, and underscores the challenges in disease activity assessment. US examination may be a valuable objective tool in the evaluation of these patients.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001422/pdfft?md5=4943a849cb50e2038e5187cde85c5dff&pid=1-s2.0-S0049017224001422-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}